Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma

Trial Profile

A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs SAR 260301 (Primary) ; Vemurafenib
  • Indications Lymphoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Sanofi
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 04 Oct 2017 Status changed from recruiting to discontinued, according to the results published in the Cancer.
    • 04 Oct 2017 Results (n=21) assessing the maximum tolerated dose, safety, pharmacokinetics, pharmacodynamics, and efficacy of the selective PI3Kb inhibitor SAR260301 in patienstw with advanced solid tumors, published in the Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top